Beacon Software | $250,000,000 | (Nov 5, 2025)
Downstream | $8,000,000 | (Nov 5, 2025)
Ruli | $6,000,000 | (Nov 5, 2025)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
Mine Vision Systems | $12,500,000 | (Nov 5, 2025)
Planbase (YC S24) | $2,100,000 | (Nov 5, 2025)
The EVERY Company | $55,000,000 | (Nov 5, 2025)
Daylight Security | $33,000,000 | (Nov 5, 2025)
Azalea Therapeutics | $82,000,000 | (Nov 5, 2025)
Parable | $11,000,000 | (Nov 5, 2025)
Sunflower Labs | $16,000,000 | (Nov 5, 2025)
C.Scale | $2,000,000 | (Nov 5, 2025)
Portal26 | $9,000,000 | (Nov 5, 2025)